CY1123750T1 - Μεθοδοι για την αξιολογηση μιας ανοσοαποκρισης σε εναν θεραπευτικο παραγοντα - Google Patents

Μεθοδοι για την αξιολογηση μιας ανοσοαποκρισης σε εναν θεραπευτικο παραγοντα

Info

Publication number
CY1123750T1
CY1123750T1 CY20201101094T CY201101094T CY1123750T1 CY 1123750 T1 CY1123750 T1 CY 1123750T1 CY 20201101094 T CY20201101094 T CY 20201101094T CY 201101094 T CY201101094 T CY 201101094T CY 1123750 T1 CY1123750 T1 CY 1123750T1
Authority
CY
Cyprus
Prior art keywords
methods
immune response
antibody titer
assessing
therapeutic agent
Prior art date
Application number
CY20201101094T
Other languages
English (en)
Inventor
Meena Subramanyam
Lakshmi Amaravadi
Eric Wakshull
Michael Panzara
Robin Mcdaid Barbour
Julie Elizabeth Taylor
Original Assignee
Biogen Ma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37023063&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1123750(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen Ma Inc. filed Critical Biogen Ma Inc.
Publication of CY1123750T1 publication Critical patent/CY1123750T1/el

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/686—Anti-idiotype
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70546—Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/285—Demyelinating diseases; Multipel sclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)

Abstract

Η εφεύρεση αφορά μεθόδους και προϊόντα για την ταυτοποίηση μίας κλινικά σημαντικής ανοσοαπόκρισης σε υποκείμενα που υποβάλλονται σε αγωγή με μία θεραπευτική πρωτεΐνη. Μορφές της εφεύρεσης αφορούν μεθόδους και συνθέσεις για την ταυτοποίηση μίας κλινικά σημαντικής ανοσοαπόκρισης σε ασθενείς που υποβάλλονται σε αγωγή με θεραπευτικές ποσότητες δέσμευσης VLA-4 (π.χ., ναταλιζουμάμπη). Μία δεύτερη μορφή της εφεύρεσης αφορά τις χρονολογικές λεπτομέρειες της συλλογής δειγμάτων για τον καθορισμό του τίτλου αντισωμάτων έναντι της θεραπευτικής πρωτεΐνης, π.χ. της συλλογής τουλάχιστον δύο δειγμάτων σε δύο διαφορετικά χρονικά σημεία. Μία τρίτη μορφή της εφεύρεσης αφορά την επιλογή του κρίσιμου επιπέδου κατωφλίου που αντιστοιχεί προς τον τίτλο αντισώματος μη υποβληθέντων σε αγωγή ασθενών αυξημένο κατά το διπλάσιο της τυπικής απόκλισης αυτού του συγκριτικού τίτλου αντισώματος.
CY20201101094T 2005-04-04 2020-11-18 Μεθοδοι για την αξιολογηση μιας ανοσοαποκρισης σε εναν θεραπευτικο παραγοντα CY1123750T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US66840405P 2005-04-04 2005-04-04
EP13158951.7A EP2645106B1 (en) 2005-04-04 2006-04-04 Methods for evaluating an immune response to a therapeutic agent
EP06749243.9A EP1872136B9 (en) 2005-04-04 2006-04-04 Methods and products for evaluating an immune response to a therapeutic protein
PCT/US2006/012493 WO2006107962A2 (en) 2005-04-04 2006-04-04 Methods and products for evaluating an immune response to a therapeutic protein

Publications (1)

Publication Number Publication Date
CY1123750T1 true CY1123750T1 (el) 2022-03-24

Family

ID=37023063

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20171100973T CY1119412T1 (el) 2005-04-04 2017-09-14 Μεθοδοι για την αξιολογηση μιας ανοσοαποκρισης σε εναν θεραπευτικο παραγοντα
CY20201101094T CY1123750T1 (el) 2005-04-04 2020-11-18 Μεθοδοι για την αξιολογηση μιας ανοσοαποκρισης σε εναν θεραπευτικο παραγοντα

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20171100973T CY1119412T1 (el) 2005-04-04 2017-09-14 Μεθοδοι για την αξιολογηση μιας ανοσοαποκρισης σε εναν θεραπευτικο παραγοντα

Country Status (20)

Country Link
US (5) US8124350B2 (el)
EP (4) EP3796003A1 (el)
JP (3) JP2008537595A (el)
CN (1) CN101351710B (el)
AU (1) AU2006231511B2 (el)
CA (2) CA2603481C (el)
CY (2) CY1119412T1 (el)
DK (2) DK2645106T3 (el)
ES (3) ES2536915T5 (el)
HK (2) HK1112059A1 (el)
HR (2) HRP20171310T1 (el)
HU (2) HUE052412T2 (el)
IL (1) IL186431A (el)
LT (2) LT3264094T (el)
NZ (1) NZ562784A (el)
PL (2) PL2645106T3 (el)
PT (2) PT2645106T (el)
RS (2) RS56418B1 (el)
SI (2) SI2645106T1 (el)
WO (1) WO2006107962A2 (el)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003213231A1 (en) 2002-02-25 2003-09-09 Elan Pharmaceuticals, Inc. Administration of agents for the treatment of inflammation
LT3264094T (lt) 2005-04-04 2021-04-12 Biogen Ma Inc. Imuninio atsako į terapijos agentą įvertinimo būdai
US20070207141A1 (en) 2006-02-28 2007-09-06 Ivan Lieberburg Methods of treating inflammatory and autoimmune diseases with natalizumab
JP5504390B2 (ja) 2006-03-03 2014-05-28 バイオジェン・アイデック・エムエイ・インコーポレイテッド ナタリズマブを用いて炎症性疾患及び自己免疫疾患を治療する方法
CN103399145B (zh) * 2007-12-15 2015-06-24 霍夫曼-拉罗奇有限公司 区分测定
WO2009091240A1 (en) * 2008-01-15 2009-07-23 Stichting Sanquin Bloedvoorziening Method and kits for detecting antibodies against therapeutic antibodies
WO2011044553A1 (en) 2009-10-11 2011-04-14 Biogen Idec Ma Inc. Anti-vla-4 related assays
US11287423B2 (en) 2010-01-11 2022-03-29 Biogen Ma Inc. Assay for JC virus antibodies
PL2524060T3 (pl) 2010-01-11 2018-05-30 Biogen Ma Inc. Test wykrywający przeciwciała przeciwko wirusowi jc
CA2802278A1 (en) * 2010-08-19 2012-02-23 Veit Peter Grunert An assay for measurement of antibodies binding to a therapeutic monoclonal antibody
EP3326645B1 (en) * 2010-10-25 2020-03-18 Biogen MA Inc. Methods for determining differences in alpha-4 integrin activity by correlating differences in svcam and/or smadcam levels
WO2012175201A1 (en) * 2011-06-20 2012-12-27 Cellzome Ag Methods for the characterization of antibodies
EP3004334A4 (en) 2013-05-28 2016-12-21 Biogen Ma Inc METHODS OF EVALUATION RISK OF DEVELOPMENT OF PML
CN103439515B (zh) * 2013-08-14 2015-07-15 南方医科大学 一种抗体效价的检测方法
US20170059561A1 (en) * 2015-08-28 2017-03-02 The Florida International University Board Of Trustees Thermally Stable Electrochemical Sensor With Long Shelf-Life
US20200323772A1 (en) * 2017-08-15 2020-10-15 Progenity, Inc. Treatment of inflammatory disease using ingestible device to release immune modulator
CN112730846B (zh) * 2020-12-18 2023-12-15 安渡生物医药(杭州)有限公司 一种用于小鼠血样检测免疫复合物的方法

Family Cites Families (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3639350A (en) 1970-04-15 1972-02-01 Allied Chem Esterification of terephthalic acid with an alkylene glycol in the presence of guanidine or an alkyl guanidine
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4425112A (en) 1976-02-25 1984-01-10 The United States Of America As Represented By The Department Of Health And Human Services Flow-through centrifuge
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4235601A (en) 1979-01-12 1980-11-25 Thyroid Diagnostics, Inc. Test device and method for its use
US4391904A (en) 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4517288A (en) 1981-01-23 1985-05-14 American Hospital Supply Corp. Solid phase system for ligand assay
US4472509A (en) 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
US4703017C1 (en) 1984-02-14 2001-12-04 Becton Dickinson Co Solid phase assay with visual readout
US4938948A (en) 1985-10-07 1990-07-03 Cetus Corporation Method for imaging breast tumors using labeled monoclonal anti-human breast cancer antibodies
CA1291031C (en) 1985-12-23 1991-10-22 Nikolaas C.J. De Jaeger Method for the detection of specific binding agents and their correspondingbindable substances
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5763262A (en) 1986-09-18 1998-06-09 Quidel Corporation Immunodiagnostic device
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2 Inc Geänderte antikörper.
DE3887771C5 (de) 1987-04-27 2009-06-04 Inverness Medical Switzerland Gmbh Immunoassays und Vorrichtungen dafür.
US4943522A (en) 1987-06-01 1990-07-24 Quidel Lateral flow, non-bibulous membrane assay protocols
US5120643A (en) 1987-07-13 1992-06-09 Abbott Laboratories Process for immunochromatography with colloidal particles
US4818677A (en) 1987-12-03 1989-04-04 Monoclonal Antibodies, Inc. Membrane assay using focused sample application
AU2684488A (en) 1988-06-27 1990-01-04 Carter-Wallace, Inc. Test device and method for colored particle immunoassay
US5221616A (en) 1988-07-15 1993-06-22 Quidel Corporation Prevention of spontaneous complement activation in mammalian biological fluids
US5118630A (en) 1988-11-04 1992-06-02 Quidel Corporation Method for determining periodic infertility in females
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US6352862B1 (en) 1989-02-17 2002-03-05 Unilever Patent Holdings B.V. Analytical test device for imuno assays and methods of using same
US5084828A (en) 1989-09-29 1992-01-28 Healthtech Services Corp. Interactive medication delivery system
US5252496A (en) 1989-12-18 1993-10-12 Princeton Biomeditech Corporation Carbon black immunochemical label
US5096837A (en) 1990-02-08 1992-03-17 Pacific Biotech, Inc. Immunochromatographic assay and method of using same
US5223220A (en) 1990-03-27 1993-06-29 Pacific Biotech, Inc. Solid phase immunoassay device and method of making same
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5118428A (en) 1990-11-13 1992-06-02 Quidel Method to remove red blood cells from whole blood samples
DE4139840B4 (de) 1990-12-04 2005-06-02 Quidel Corp., San Diego Antigen-Zubereitung zum Nachweis von H. pylori
EP0566695B1 (en) 1991-01-11 1999-06-02 Quidel Corporation A one-step lateral flow assay and nonbibulous support used therein
US5225328A (en) 1991-05-30 1993-07-06 Quidel Corporation Stable alkaline phosphatase compositions with color enhancement and their use in assays
US5686315A (en) 1991-06-14 1997-11-11 Quidel Corporation Assay device for one step detection of analyte
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
JPH07503543A (ja) 1992-02-04 1995-04-13 クイデル　コーポレイション 乾燥試薬を用いる細菌抗原の簡易化抽出法
US5541069A (en) 1992-02-28 1996-07-30 Quidel Corporation Assay having improved dose response curve
ES2151902T3 (es) 1992-03-10 2001-01-16 Quidel Corp Medio de separacion de globulos rojos para dosificarlos mediante union especifica.
ATE182625T1 (de) 1993-01-12 1999-08-15 Biogen Inc Rekombinante anti-vla4 antikörpermoleküle
DK0682529T4 (da) 1993-02-09 2006-05-15 Biogen Idec Inc Antistof til behandling af insulinkrævende diabetes
US5415994A (en) 1993-08-02 1995-05-16 Quidel Corporation Lateral flow medical diagnostic assay device with sample extraction means
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US5434057A (en) 1994-02-02 1995-07-18 Quidel Corporation Sperm motility assay and devices
US5521102A (en) 1994-08-08 1996-05-28 Quidel Corporation Controlled sensitivity immunochromatographic assay
US5845255A (en) 1994-10-28 1998-12-01 Advanced Health Med-E-Systems Corporation Prescription management system
US5712172A (en) 1995-05-18 1998-01-27 Wyntek Diagnostics, Inc. One step immunochromatographic device and method of use
US5804452A (en) 1995-04-27 1998-09-08 Quidel Corporation One step urine creatinine assays
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5786220A (en) 1995-04-28 1998-07-28 Quidel Corporation Assays and devices for distinguishing between normal and abnormal pregnancy
US20010051350A1 (en) 1995-05-02 2001-12-13 Albert Nazareth Diagnostic detection device and method
US5773234A (en) 1995-08-07 1998-06-30 Quidel Corporation Method and device for chlamydia detection
DE19541844C1 (de) 1995-11-09 1997-07-24 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von menschlichen Antikörpern und deren Verwendung
DE19543553B4 (de) 1995-11-22 2009-04-09 Deutsches Primatenzentrum Gmbh VP-Antigene des JC-Virus
KR20080059467A (ko) 1996-12-03 2008-06-27 아브게닉스, 인크. 복수의 ｖｈ 및 ｖｋ 부위를 함유하는 사람 면역글로불린유전자좌를 갖는 형질전환된 포유류 및 이로부터 생성된항체
US6305377B1 (en) 1996-12-12 2001-10-23 Michael T. Portwood System and method for improving compliance of a medical regimen
US6306642B1 (en) 1997-11-24 2001-10-23 Quidel Corporation Enzyme substrate delivery and product registration in one step enzyme immunoassays
JPH11190734A (ja) * 1997-12-26 1999-07-13 Wakamoto Pharmaceut Co Ltd クローン病の検査方法および検査用キット
US6623981B2 (en) 1998-01-27 2003-09-23 Bristol-Myers Squibb Company Detection of patients at risk for developing integrin antagonist/agonist mediated disease states
US6014631A (en) 1998-04-02 2000-01-11 Merck-Medco Managed Care, Llc Computer implemented patient medication review system and process for the managed care, health care and/or pharmacy industry
US6045501A (en) 1998-08-28 2000-04-04 Celgene Corporation Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug
US7171371B2 (en) 1999-09-03 2007-01-30 Smg Trust Method and system for providing pre and post operative support and care
US7129053B1 (en) 1999-10-12 2006-10-31 Dakocytomation Denmark A/S Immuno-chromatographic rapid assay in order to detect acid-resistant microorganisms in the stool
US6612032B1 (en) 2000-01-31 2003-09-02 Lexmark International, Inc. Manufacturing method for ink jet pen
EP1271152A4 (en) 2000-03-30 2005-04-27 Nippon Kayaku Kk METHOD FOR DETECTING CANCER BY MEASURING AUTOANTIC VIRUSES AGAINST MDM2 AND REAGENTS THEREFOR
US8288322B2 (en) 2000-04-17 2012-10-16 Dyax Corp. Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries
US7018847B2 (en) 2000-05-05 2006-03-28 Pharmacia Diagnostics Ab Assay device with timer function
US6620626B1 (en) 2000-08-09 2003-09-16 Mission Research Corp. Antigen detection device and method
JP2002071694A (ja) * 2000-08-25 2002-03-12 Wakamoto Pharmaceut Co Ltd 炎症性腸疾患の検査方法及び検査用キット
WO2002033417A1 (en) 2000-10-17 2002-04-25 Besst-Test Aps Assay for directly detecting a rs virus related biological cell in a body fluid sample
US6315720B1 (en) 2000-10-23 2001-11-13 Celgene Corporation Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug
US6485460B2 (en) 2001-01-12 2002-11-26 Bracco Diagnostics, Inc. Tamper evident syringe barrel
US7291477B2 (en) 2001-07-03 2007-11-06 Xenotope Diagnostics, Inc. Method and device for trichomonas detection
WO2003016909A1 (en) * 2001-08-16 2003-02-27 Ludwig Institute For Cancer Research Method for determining protein component in a biological sample
CA2457930C (en) 2001-08-20 2012-06-19 Proteome Systems Intellectual Property Pty Ltd. Diagnostic testing process and apparatus
AU2003213231A1 (en) 2002-02-25 2003-09-09 Elan Pharmaceuticals, Inc. Administration of agents for the treatment of inflammation
DE60336848D1 (de) * 2002-09-12 2011-06-01 Univ California Immunogene und entsprechende antikörper, die spezifisch sind für häufige hochmolekulare aggregations-zwischenprodukte von amyloiden aus proteinen unterschiedlicher sequenz
CA2502926A1 (en) * 2002-11-08 2004-05-27 Linda J. Sandell Uncoupled collagen synthesis and degradation assays
RU2370775C2 (ru) * 2003-07-29 2009-10-20 Дженентек, Инк. Анализ нейтрализующих антител и его применение
US7238538B2 (en) 2003-09-19 2007-07-03 Freitag Helmut E Chromatographic assay device and methods
JP4933258B2 (ja) 2003-09-22 2012-05-16 クイデル コーポレーション 試料中の複数分析物の検出装置
JP4672263B2 (ja) 2004-01-27 2011-04-20 デンカ生研株式会社 簡便な検出法、検出装置及び検出キットとその製法
US7419666B1 (en) 2004-02-23 2008-09-02 Massachusetts Eye And Ear Infirmary Treatment of ocular disorders
US20050283385A1 (en) 2004-06-21 2005-12-22 The Permanente Medical Group, Inc. Individualized healthcare management system
US8445293B2 (en) 2005-02-09 2013-05-21 Rapid Pathogen Screening, Inc. Method to increase specificity and/or accuracy of lateral flow immunoassays
ES2387317T3 (es) 2005-03-03 2012-09-20 Seedlings Life Science Ventures, Llc. Procedimiento de control de riesgos de pacientes en tratamiento con natalizumab
LT3264094T (lt) * 2005-04-04 2021-04-12 Biogen Ma Inc. Imuninio atsako į terapijos agentą įvertinimo būdai
US20060246513A1 (en) 2005-05-02 2006-11-02 Bohannon Robert C Method and device to detect the presence of analytes in a sample
CA2641160A1 (en) 2006-02-28 2007-09-07 Elan Pharmaceuticals, Inc. Methods of treating inflammatory and autoimmune diseases with alpha-4 inhibitory compounds
US20070207141A1 (en) 2006-02-28 2007-09-06 Ivan Lieberburg Methods of treating inflammatory and autoimmune diseases with natalizumab
JP5504390B2 (ja) 2006-03-03 2014-05-28 バイオジェン・アイデック・エムエイ・インコーポレイテッド ナタリズマブを用いて炎症性疾患及び自己免疫疾患を治療する方法
AU2007280929B2 (en) 2006-07-26 2012-03-22 Abbott Rapid Diagnostics International Unlimited Company Analysis device for biological sample
US7704702B2 (en) 2006-08-10 2010-04-27 Inverness Medical Switzerland Gmbh Test strip for lateral flow assays
EP2089515A4 (en) 2006-11-16 2011-02-23 Novavax Inc VIRUSUAL PARTICLES OF RESPIRATORY SYNZYTIAL VIRUS
EP1933140B1 (en) 2006-12-11 2011-08-17 AraGen Biotechnology Co. Ltd. Antibody detection method involving an oligonucleotide enhanced collodial gold signal
JP2010537633A (ja) 2007-08-30 2010-12-09 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ コンプライアント表面のマルチウェル培養プレート
PL2524060T3 (pl) 2010-01-11 2018-05-30 Biogen Ma Inc. Test wykrywający przeciwciała przeciwko wirusowi jc

Also Published As

Publication number Publication date
PT2645106T (pt) 2017-09-18
EP3796003A1 (en) 2021-03-24
JP2014197032A (ja) 2014-10-16
US10705095B2 (en) 2020-07-07
ES2536915T3 (es) 2015-05-29
RS61229B1 (sr) 2021-01-29
EP2645106A2 (en) 2013-10-02
RS56418B1 (sr) 2018-01-31
AU2006231511B2 (en) 2012-02-16
HUE052412T2 (hu) 2021-04-28
CY1119412T1 (el) 2018-03-07
WO2006107962A9 (en) 2007-04-19
EP3264094B1 (en) 2020-08-19
LT2645106T (lt) 2017-09-11
IL186431A0 (en) 2008-01-20
EP2645106A3 (en) 2013-10-09
NZ562784A (en) 2010-07-30
DK2645106T3 (en) 2017-10-02
HRP20171310T1 (hr) 2017-12-15
CN101351710A (zh) 2009-01-21
US20120195884A1 (en) 2012-08-02
WO2006107962A8 (en) 2008-01-24
CN101351710B (zh) 2013-06-05
DK3264094T3 (da) 2020-11-23
WO2006107962A2 (en) 2006-10-12
SI3264094T1 (sl) 2021-04-30
WO2006107962A3 (en) 2007-03-08
ES2640295T3 (es) 2017-11-02
PL2645106T3 (pl) 2017-11-30
HK1245884A1 (zh) 2018-08-31
JP6044904B2 (ja) 2016-12-14
PL3264094T3 (pl) 2021-04-19
PT3264094T (pt) 2020-11-24
ES2536915T5 (es) 2023-03-01
US20180088127A1 (en) 2018-03-29
US20090176256A1 (en) 2009-07-09
CA3031792A1 (en) 2006-10-12
LT3264094T (lt) 2021-04-12
EP1872136B2 (en) 2022-11-16
CA2603481C (en) 2019-03-12
EP1872136B9 (en) 2023-02-08
EP3264094A1 (en) 2018-01-03
SI2645106T1 (en) 2018-01-31
HK1112059A1 (en) 2008-08-22
HRP20201840T1 (hr) 2021-04-02
US8871449B2 (en) 2014-10-28
EP2645106B1 (en) 2017-06-14
IL186431A (en) 2012-03-29
HUE034318T2 (en) 2018-02-28
EP1872136A2 (en) 2008-01-02
EP1872136B1 (en) 2015-02-18
AU2006231511A1 (en) 2006-10-12
US8124350B2 (en) 2012-02-28
US20150071917A1 (en) 2015-03-12
ES2833948T3 (es) 2021-06-16
US11686734B2 (en) 2023-06-27
JP2008537595A (ja) 2008-09-18
US20210025900A1 (en) 2021-01-28
US9709575B2 (en) 2017-07-18
JP2012008146A (ja) 2012-01-12
CA2603481A1 (en) 2006-10-12

Similar Documents

Publication Publication Date Title
CY1123750T1 (el) Μεθοδοι για την αξιολογηση μιας ανοσοαποκρισης σε εναν θεραπευτικο παραγοντα
JP2019530875A5 (el)
ATE411525T1 (de) Nachweis einer histonmodifikation in zellfreien nukleosomen
CY1119972T1 (el) Προσδιορισμος για αντισωματα ιου jc
MX2007014815A (es) Metodos de inmunoanalisis mejorados.
IL188460A0 (en) Diagnostic methods and compositions for diagnosing and treating influenza
BRPI0715126B8 (pt) métodos para avaliação do risco de intervenções cardíacas e usos à base de gdf-15
WO2006026020A3 (en) Oncofetal fibronectin as a marker for disease and other conditions and methods for detection of oncofetal fibronectin
MY162697A (en) Methods, devices and kits for detecting or monitoring acute kidney injury
DE602005013225D1 (de) Aptamer-nanopartikelkonjugate und verwendungsverfahren zur detektion von zielanalyten
CY1108182T1 (el) Μεσα εντοπισμου του παθολογικου μετασχηματισμου της πρωτεϊνης app και εφαρμογες τους
MX2009013388A (es) Analisis multiple de muestras de sangre.
WO2006124526A3 (en) Method for assessing the effectiveness of a treatment regimen by determining zonulin
ATE405832T1 (de) Verfahren zur erhöhung des dynamischen messbereichs von auf spezifischen bindereaktionen basierenden, insbesondere immunologischen testelementen
EP2210939A4 (en) ANTIBODY ANTI-BST2
DK2185939T3 (da) Engangsanalyseudstyr med mikroprocessor
ATE474228T1 (de) Reagenz für hämoglobinabbau
DE60315715D1 (de) Verwendung von nicotinamide n-methyltransferase zur diagnose von kolorektalem krebs
GB2437545B (en) Dextrin-containing reagents for detecting and quantifying proteins
ATE492815T1 (de) Diagnostik-biomolekül(e)
DE602005013430D1 (de) Verwendung von asc als marker für kolorektalkarzinome
CY1113013T1 (el) Βελτιωμενες μεθοδοι ανοσολογικων δοκιμασιων
JP2017524689A5 (el)
WO2009108170A3 (en) Compositions and methods for determining immune status
WO2005102938A3 (en) Antibodies specific for bcr-abl fusion protein and uses thereof